Member Info for Trickymatters

Not too shabby hey? Oversubscribed and a nice $12 million in the bank to take them through to takeover. International kidney day on Thursday. Hoping to see a bit of coverage.

Just checked Nasdaq. It's up to the equivalent of 35p. Which is why we're up. Happens every day. Big volume. Aim is embarrassing.

Correcting an earlier post of mine. Unicorn took 1.1% on 4th March after the takeover announcement. Pentwater took 4%. The latter have specialist teams for health and AI. Hmm. Total coincidence?

Apologies for my earlier mistake.

Hawker, yeah the shorters seem to be implying that Christopher Mills involvement and Harwood's involvement is no biggie. Harwood were small cap investment fund of the year in 2023, taking 1st, 2nd and 3rd place. They specialise in M&A and helping small companies to realise their potential. Mills has had several 10 baggers in his portfolio. This will be a 7-8 bagger from here, assuming the consultation goes well. The problem with looking at the sp day to day is that it's stressful and people sell causing volatility. This is only going one way - give it time. Shorters are making some ridiculous and nonsensical comparisons.

The US insurance industry finishes it's consultation next week. Recommendations to follow thereafter. The price is set at $950.00 a test. 10 million people in the US have diabetes 2, predicted to rise. If nothing is done kidney disease will become the 4th biggest cause of death in the US. Something will be done. There's a Democrat in the top job. Thank goodness.

I think SB's theory that this is going to iis is likely. Harwood et al will probably take the lot. They're hardly 'bucket shop'. They are all well connected. I expect they know who the bidder is and they definitely know what the business case is because it's all in the public domain. US insurance coverage for all citizens who may have or may at some point get type 2 diabetes or chronic kidney disease. It's in the insurance industry interest to get better engagement with this group because they spend 7 times as much on acute kidney disease and dialysis than they do on treatment for chronic kidney disease. Reckon Thermo Fischer and Astra Zeneca will end up fighting it out for the takeover whoever's bid atm. Worth another $5 billion just on additional drug treatment - once early detection is achieved they can prevent acute disease forming but they can't reverse it.

This stock has gone up 170% in less than a month. Of course the shorters are getting excited. The US pushed it up 650% at one point. We all know they need cash. Maj the self appointed guru said this would be 10p for the placing. He pretends he's connected. Now he says 18-20p. Changed his mind already. Shorts are mostly closing. Institutional investors are buying in. Unicorn just took 4%.

I'm not fascinated by what the shorts are doing. I am interested in the business case for this product. It's very good. As I have discussed. Maj doesn't engage with the business case. He focuses on the volatility in the sp to scare people into selling. It can go up just as fast as it can go down. There still aren't that many shares in issue considering the potential for a decent price at takeover.

I think the bidder may have put a caveat on the offer- ie. subject to the insurance industry in the US recommending the test. That would be sensible wouldn't it? They will disclose when the outcome of the consultation is announced imho.

Unlike all the tiny shares you shorters keep banging on about this company is 10 days from the end of a consultation process to extend US Medicare and other medical insurance coverage to it's product, right across the US. That's why people are buying. Because they will get bought out. The decision will be taken within a few weeks or months. I will put money on the US insurance authority recommending that test. That's all that matters. Then the offers are coming in because they have patented the test. The US Government, the Veterans Association have already started buying. The consultation is being undertaken on the assumption that it will be adopted. Read the press coverage. There's a strong business case for it to be adopted for the insurance industry and those pharma companies who sell drugs for chronic kidney disease. This could be part of a preventative strategy to vastly reduce acute kidney disease. That's the stated aim of Astra Zeneca.

I am disappointed that they raised at 20p. Should have raised at 40p but I suppose they will be on the back foot because they left it this late.

Don't blame either me for 'ramping the shares to 70p'. They went there all on their own because the US market took them there.

Harwood Capital bought 10% last week. Polar Capital bought 4%. Shorters Citadel are down, Armistice down and Millennium are down. International kidney day on Thursday. And the consultation for the US authorities governing the medical insurance industry ends next week. They have already recommended this test for $950 dollars each. The market in the US alone is an estimated 10-14 million people with type 2 diabetes or chronic kidney disease. The US government has just agreed a contract with RENX to cover all of their armed services. But of a vote of confidence.

This is very likely to happen imho. It will save US insurers about $35 billion on kidney dialysis and other acute treatment for failing kidneys. It will save hundreds of thousands of lives. And big pharma like AstraZeneca will probably double the sales of their chronic treatments already worth about $5 billion. Kidney disease is a big cause of early mortality in the world and destined to become the 4th largest unless we do something about it. Kidney disease can't be reversed but it can be managed and prevented from getting worse if it's caught in time.

$1.11 now on Nasdaq. 43p. Just climbs every day whatever we give it to them at. The US understands that when this gets nationwide insurance coverage, (currently in consultation for exactly that) the current bid will quickly become just a baseline for competitor challenges.

Shorters are closing Maj. Check it out on the short tracker. Soon there will just be you amid a stampeding herd of bulls😄

Nowt wrong with Harl's sustainability as a company SSam. But we need to get Riverfort out if we're ever going to see value as shareholders. Not long now by the looks of it.

Yeah, the Times will have probably got the story right. But if HARL wanted to wait until the whole set of new arrangements to replace Riverfort were in place that'll be inconvenient. Still if the agreement is in place they should be RNSing.

Who cares if the opposition are scoring points. That's what they are paid to do. Labour will be way more likely to back all kinds of British businesses. HARL included. They certainly won't renege on a government contract which has already been awarded.

The Times coverage suggests that we'll get confirmation of UKEF funding any time. They're telling the world and it's oyster that we've got it. They might wait until the new funding arrangement with banks is in place but they shouldn't wait to long- UKEF funding confirmation is news that we haven't had before.

Think there'll be coverage. AstraZeneca are a leading sponsor.

The broker says they'll get £2.00.

Assets of £2billion for investment. They also act for Rockwood Strategic plc who are based in the US. Assets of $39 billion under management.

Wonder if they are buying on behalf of the buyer? If not there's a leak surely?

*NB. 10-14 million people in the US are at risk of kidney disease. My whole example is based on the US because they are most influential on the sp right now, since they are the one's taking the decision to apply US Medicare coverage nationwide for this product.

Worldwide it's 85 million at the moment.

Yes. Looks like a genuine investment- it fits their investment profile. They think AI will be an abiding growth factor for healthcare, helping with personalised medicine, saving clinicians time and supporting prevention. I think their analysts are reading our posts😄

We have to recognise how many win- wins Kidneyintel offers.

1. It will reduce US insurance costs by about $35 billion a year if it can reduce acute kidney disease- stage 4 and 5. The decision makers consulting on adopting this technology already say it is reasonable and necessary for people with type 2 diabetes.

2. For drug companies drugs to aid chronic kidney disease will see increased demand as more people engage and are diagnosed- we miss most of those with chronic kidney disease and only find out when they are already experiencing acute kidney disease or kidney failure. AZN made $5 billion on the very new drug for chronic kidney disease last year.

3. 10-14 million people are at risk of kidney disease. AZN is campaigning to extend kidney screening beyond 35 million people worldwide for the initial World Kidney Day target.

4. Kidney disease is expected to become the 4th highest reason for early mortality in the next 10 years unless something is done to reverse current trends. Acute kidney disease and kidney failure costs the US health system alone, $35 billion. And it's a fatal disease if it isn't caught in time but it's possible to prevent it's progress to acute and life threatening stages if detected in time.

The $950 price will be subsidised imho. The consultation process ends in in the 3rd week of March.

Polar Capital have taken 4.1%. Wow. Ridiculously successful investment firm. Their website is all about AI as a disruptive influence at the moment. All bodes well.

Anyone could see AVACTA were going down. KOD ditto. Etc. Anyone could have shorted those shares for obvious reasons. Most of us don't short because it's a nasty business to get into. Maj is trying to imply his sociopathic choices equate to a higher intelligence. A general theme of his posts.

Personalising the conversation instead of focusing on the obvious fact that this stock is coming to the end of a 6 week consultation for national health insurance coverage in the US. The insurance industry has a vested interest in agreeing this coverage because it poses maximum direct savings to them of over $35 billion (the cost of severe kidney disease).

If maximum take up of those at risk of chronic kidney disease were achieved the costs of the tests would be over $9 billion. The incentive to company's like AZN is also clear. They make over $5 billion a year from drugs to treat chronic disease. Demand for that treatment will increase if more people are detected early. Less people will end up on more expensive dialysis however less people will die and less people will have to have kidney replacement surgery which is dependent on donors.